Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988-2009

Croatian Medical Journal

Volumn 53, Issue 2, 2012, Pages 115-123

  Novak, Ina ^a   Jakšić, Ozren ^b   Kuliš, Tomislav ^c   Batinjan, Katarina ^a   Znaor, Ariana ^a,d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Zagreb School of Medicine   (Croatia)

^c KBC Zagreb   (Croatia)

^d CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CROATIA; FEMALE; GROUPS BY AGE; HODGKIN DISEASE; HUMAN; INFANT; LEUKEMIA; LYMPHATIC LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NEWBORN; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; CHILD, PRESCHOOL; CROATIA; FEMALE; HUMANS; INCIDENCE; INFANT; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84862542387     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2012.53.115     Document Type: Article

References (53)

1. Croatian National Cancer Registry, Croatian National Institute of Public Health. Cancer incidence in Croatia 1975-2009. Bulletins No 1-34. Zagreb, Croatia: Croatian National Institute of Public Health; 1985-2010.
2. Brenner H, Francisci S, de Angelis R, Marcos-Gragera R, Verdecchia A, Gatta G, et al. Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer. 2009;45:1028-41.
3. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994;137(2 Suppl):S68-97.
4. Fabrikant JI. The carcinogenic risks of low-LET and high-LET ionizing radiations. J Radiat Res (Tokyo). 1991;32:143-64.
5. Daniels RD, Schubauer-Berigan MK. A meta-analysis of leukemia risk from protracted exposure to low-dose gamma radiation. Occup Environ Med. 2011;68:457-64.
6. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health. 2010;9:31.
7. Turner MC, Wigle DT, Krewski D. Residential pesticides and childhood leukemia: a systematic review and meta-analysis. Cien Saude Colet. 2011;16:1915-31.
8. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745-51.
9. Kane EV, Roman E, Cartwright R, Parker J, Morgan G. Tobacco and the risk of acute leukemia in adults. Br J Cancer. 1999;81:1228-33.
10. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099-107.
11. Xavier AC, Taub JW. Acute leukemia in children with Down syndrome. Haematologica. 2010;95:1043-5.
12. Crowther-Swanepoel D, Houlston RS. Genetic variation and risk of chronic lymphocytic leukemia. Semin Cancer Biol. 2010;20:363-9.
13. Takatsuki K. Adult T-cell leukemia. Intern Med. 1995;34:947-52.
14. Poole C, Greenland S, Luetters C, Kelsey JL, Mezei G. Socioeconomic status and childhood leukemia: a review. Int J Epidemiol. 2006;35:370-84.
15. Lichtman MA. Obesity and the risk for a haematologicallogical malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083-101.
16. Cocco P, t'Mannetje A, Fadda D, Melis M, Becker N, de Sanjose S, et al. Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study. Occup Environ Med. 2010;67:341-7.
17. Besson H, Brennan P, Becker N, De Sanjose S, Nieters A, Font R, et al. Tobacco smoking, alcohol drinking and Hodgkin's lymphoma: a European multi-centre case-control study (EPILYMPH). Br J Cancer. 2006;95:378-84.
18. Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997;73:645-50.
19. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risk to humans, Vol 67. Human immunodeficiency virus and human lymphotrophic T-cell viruses. Lyon (France): IARC press; 1996.
20. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risk to humans, Vol 70. Epsterin-Barr virus and Kaposi's sarcoma Herpesvirus/Human Herpesvirus 8. Lyon (France): IARC press; 1998.
21. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al, editors. Cancer incidence in five continents, Vol IX (IARC Scientific Publications No. 160). Lyon (France): IARC; 2007.
22. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents, Vol VII (IARC Scientific Publications No. 143). Lyon (France): IARC; 1997.
23. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer Incidence in five continents, Vol VIII (IARC Scientific Publications No. 155). Lyon (France): IARC; 2002.
24. International Classification of Diseases (ICD). Available from: http://www.who.int/classifications/icd/en/. Accessed: February 12, 2011.
25. World Health Organization. World Health Organization mortality database. WHO Statistical Information System. 2011. Available from: http://www.who.int/whosis/mort/download/en/index.html. Accessed: April 12, 2012.
26. United Nations. World population prospects, the 2010 revision. United Nations Population Division Department of Economic and Social Affairs. Available from: http://www.un.org/esa/population/unpop.htm. Accessed: February 12, 2011.
27. Doll R, Payne P, Waterhouse J. Cancer incidence in five continents: a technical report. New York (NY): Springer, 1966.
28. National Cancer Institute. Joinpoint regression program. 3.4.2 ed. Bethesda: Statistical Research and Applications Branch, National Cancer Institute, 2009.
29. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51.
30. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. In: 2010. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Accessed: February 12, 2011.
31. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al; HAEMACARE Working Group. Incidence of haematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724-34.
32. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003;97:2229-35.
33. Thygesen LC, Nielsen OJ, Johansen C. Trends in adult leukemia incidence and survival in Denmark, 1943-2003. Cancer Causes Control. 2009;20:1671-80.
34. McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas: time trends in the UK, 1984-93. Cancer Causes Control. 1999;10:35-42.
35. van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, Peters WG, et al. Chronic lymphocytic leukemia in the Netherlands: Trends in incidence, treatment and survival, 1989-2008. Eur J Cancer. 2012;48:889-95.
36. Surveillance E, Results E. (SEER) Program SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2008) Katrina/Rita Population Adjustment, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released October 2011. Available from: http://www.seer.cancer.gov. Accessed: December 2, 2011.
37. Maynadie M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica. 2011;96:55-61.
38. Adamson P, Bray F, Costantini AS, Tao MH, Weiderpass E, Roman E. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer. 2007;43:391-401.
39. Imamura Y, Mizuno S. Comparison of leukemia mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000). Jpn J Clin Oncol. 2005;35:420-3.
40. Levi F, Lucchini F, Negri E, Barbui T, La Vecchia C. Trends in mortality from leukemia in subsequent age groups. Leukemia. 2000;14:1980-5.
41. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008;93:594-600.
42. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008;93:1544-9.
43. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111:4916-21.
44. Znaor A, Brenner H, Holleczek B, Gondos A. Has there been progress in cancer care in Croatia? Assessing outcomes in a partially complete mortality follow-up setting. Eur J Cancer. 2012;48:921-8.
45. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C. The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe. Ann Oncol. 2009;20:767-74.
46. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer. 2008;123:1917-23.
47. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-42.
48. Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-71.
49. Jonsson B, Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007;18 Suppl 3:iii1-77.
50. Gratwohl A, Baldomero H, Labar B, Apperley J. Urbano-Ispizua A for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of Hematopoietic Stem Cell Transplantation in Eastern andWestern Europe from 1990 to 2003. A Report from the EBMT Activity Survey. Croat Med J. 2004;45:689-94.
51. Ana Rukavina Foundation. Available from: http://www.zakladaana-rukavina.hr/content/en/aktivnosti_zaklade/zelim_zivot.aspx#1. Accessed: April 13, 2012.
52. Gratwohl A, Baldomero H, Schwendener A, Gartwohl M, Apperley J, Frauendorfer K, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant. 2011;46:174-91.
53. Minigo H. Role of hematology the Croatian health care system [in Croatian]. Lijec Vjesn. 2007;129 Suppl 3:1.